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Abstract
Destruction of articular cartilage is a characteristic feature of osteoarthritis (OA). Collagen hydrolysates are mixtures of
collagen peptides and have gained huge public attention as nutriceuticals used for prophylaxis of OA. Here, we evaluated
for the first time whether different bovine collagen hydrolysate preparations indeed modulate the metabolism of collagen
and proteoglycans from human OA cartilage explants and determined the chemical composition of oligopeptides
representing collagen fragments. Using biophysical techniques, like MALDI-TOF-MS, AFM, and NMR, the molecular weight
distribution and aggregation behavior of collagen hydrolysates from bovine origin (CH-AlphaH, PeptanTM B 5000, PeptanTM
B 2000) were determined. To investigate the metabolism of human femoral OA cartilage, explants were obtained during
knee replacement surgery. Collagen synthesis of explants as modulated by 0–10 mg/ml collagen hydrolysates was
determined using a novel dual radiolabeling procedure. Proteoglycans, NO, PGE2, MMP-1, -3, -13, TIMP-1, collagen type II,
and cell viability were determined in explant cultures. Groups of data were analyzed using ANOVA and the Friedman test
(n = 5–12). The significance was set to p#0.05. We found that collagen hydrolysates obtained from different sources varied
with respect to the width of molecular weight distribution, average molecular weight, and aggregation behavior. None of
the collagen hydrolysates tested stimulated the biosynthesis of collagen. PeptanTM B 5000 elevated NO and PGE2 levels
significantly but had no effect on collagen or proteoglycan loss. All collagen hydrolysates tested proved not to be cytotoxic.
Together, our data demonstrate for the first time that various collagen hydrolysates differ with respect to their chemical
composition of collagen fragments as well as by their pharmacological efficacy on human chondrocytes. Our study
underscores the importance that each collagen hydrolysate preparation should first demonstrate its pharmacological
potential both in vitro and in vivo before being used for both regenerative medicine and prophylaxis of OA.
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Introduction
Collagen hydrolysates are mixtures of collagen peptides and are
popular nutriceuticals used for prophylaxis of osteoarthritis (OA).
Pharmacokinetic studies using mice showed that orally adminis-
tered radioactive gelatine hydrolysates are resorbed and that some
radioactivity is recovered within articular cartilage [1]. Collagen
hydrolysates have been considered to be a safe food ingredient
[2,3]. Clinical investigations [4–6] with various preparations of
collagen fragments consistently showed symptom-relieving effects
of collagen hydrolysates, thus improving joint function and
reducing joint pain. The methodological quality of those studies
ranged from medium to very good [7]. Interestingly, a recently
published pilot randomized controlled trial with 30 patients
presenting with mild knee OA suggests that delayed gadolinium-
enhanced magnetic resonance imaging of cartilage (dGEMERIC)
was able to detect a change in the proteoglycan content of
cartilage after 24 weeks in patients receiving a collagen hydrolysate
formulation [8]. However, these preliminary data are of limited
value due to the small sample size and missing morphometric MRI
sequences [8]. The European Food Safety Authority (EFSA) panel
on dietetic products, nutrition, and allergies recently concluded
that so far, no cause-and-effect relationship between the mainte-
nance of joints and the use of collagen hydrolysates has been
shown [9].
Collagen hydrolysates have gained huge public attention
initially due to an in vitro study published by Oesser et al. [10],
in which collagen type I hydrolysates were found to stimulate the
synthesis of proteoglycans and collagen using cultured healthy
bovine articular chondrocytes [10]. Such an effect might
antagonize the degradation and loss of matrix during progression
of OA and even be useful for tissue engineering of cartilage [11].
However, using collagen type II fragments from human and
bovine cartilage, increased matrix degradation and expression of
MMPs as well as decreased collagen type II biosynthesis were
discovered in cultured human and bovine chondrocytes or
cartilage explants [12,13]. These observations may either contrib-
ute to the OA destruction of cartilage or just be normal
endogenous metabolic feedback [12,13]. Another remarkable
study was recently published in which a ligand-receptor interac-
tion of small collagen fragments with integrin domains was
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described, which might serve as a molecular mode of action of
collagen hydrolysates [14,15].
Inflammation and catabolism are both associated with OA, and
a broad range of mediators were identified in OA joints.
Inflammatory cytokines, like interleukin-1ß (IL-1ß) and tumor
necrosis factor-a (TNF-a), have been identified as stimuli for the
biosynthesis of abnormal proteases and as inhibitors of the
production of collagen and proteoglycans by articular cartilage
[16,17]. Also, other inflammatory mediators, like nitric oxide (NO)
and prostaglandin E2 (PGE2), were reported to be involved in OA
and to interact with the cytokine-induced pathways [17,18]. For
instance, PGE2 was reported to upregulate IL-1, MMP-13, and
ADAMTS5, to inhibit synthesis but stimulate release of proteo-
glycans from OA cartilage and to contribute to synovial
inflammation [16,18,19]. NO has been proposed as an important
mediator of cartilage destruction. Excess production of NO has
been associated with decreased synthesis of aggrecan, type II
collagen, and IL-1-receptor antagonist as well as increased MMP
activity in vitro [20], thereby mediating cartilage destruction.
Identification of agents able to interfere with catabolic and
inflammatory pathways has long been a therapeutic goal for
inhibiting or slowing down the degradation of cartilage [21]. Even
though stimulated collagen biosynthesis by chondrocytes, as
reported for collagen type I hydrolysate, would be desirable, this
effect has been only observed in healthy young bovine chondro-
cytes [10]. Whether the OA cartilage of the elderly human patient
does respond similarly is speculative, since several studies have
already shown that the metabolism of OA cartilage and of older
patients is subject to severe alterations [22–24]. Furthermore, the
biosynthesis of collagen by bovine chondrocytes, as modulated by
collagen hydrolysates, was measured by the incorporation of
radioactive proline into overall proteins [10], which does not
reflect the biosynthesis of collagen type II directly. Also, no
information about collagen hydrolysates on other pathways being
involved in OA destruction has been published so far.
Thus, the present in vitro study was designed to examine for the
first time whether and to what extent collagen hydrolysates
obtained from various sources differ with respect to their biological
activities on human OA cartilage. Specifically, we were interested
to see if collagen hydrolysates 1. modulate the synthesis of collagen
type II from human OA knee cartilage, 2. differ with respect to
their chemical composition, such as molecular weight distribution
of peptides, and 3. possess the potential to induce proteoglycan
and collagen loss from cartilage explants.
Materials and Methods
MALDI-TOF Mass Spectrometric Analysis
Collagen hydrolysates from bovine origin (RDH, PeptanTM B
5000; RDH-N, PeptanTM B 2000 from Rousselot SAS, Puteaux,
France; CH-AlphaH from Gelita Health Products GmbH,
Eberbach, Germany) were used for our experiments. Using
MALDI-TOF mass spectrometry, the molecular weight distribu-
tions of peptides from collagen hydrolysates were estimated.
Collagen hydrolysates (1 mg/ml) were dissolved in water and
precipitated with acetone overnight at 220uC, centrifuged at 4uC,
and dried. Samples were redissolved in water, mixed (1:1, v:v) with
dihydroxybenzoic acid and methylendiphosphonic acid (5 mg/ml
each) used as matrix solution, and subsequently applied onto the
MALDI-TOF target as 1-ml droplets containing 1 mg collagen
hydrolysate. Sample were allowed to crystallize. All mass spectra
were acquired with a Bruker Ultraflex TOF/TOF MALDI
Figure 1. Compositional differences of collagen hydrolysates as determined by MALDI-TOF-MS. Mass spectra obtained in the (A–C)
linear and (D–F) reflector mode reveal differences between (A,D) CH-AlphaH, (B,E) RDH, and (C,F) RDH-N with respect to peptide composition, as
represented by the molecular weight distribution of the peptides, and the average molecular weight of each collagen hydrolysate preparation.
doi:10.1371/journal.pone.0053955.g001
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instrument (Bruker Daltonics, Bremen, Germany) in the positive
ion mode. The system utilizes a pulsed nitrogen laser, emitting at
337 nm. The ‘‘low mass gate’’ was set to open at m/z= 2200 for
the linear mode and at m/z= 800 for the reflector mode. An
extraction voltage of 25 kV was chosen. Each mass spectrum was
obtained as an average from 128 single laser shots. The mean
molecular weight was obtained in the linear mode and calculated
from the m/z value lying in the middle between the m/z values of
the ascending and descending peak, reaching 50% of the peak
maximum.
Atomic Force Microscopy (AFM)
AFM allows the visualization of molecular structures on a
nanoscale size. With this technique, it is possible to determine if
higher ordered structures, such as triple-helical collagen fragments,
are present. AFM was performed in the tapping mode using an
MFP-3D-Bio atomic force microscope (Atomic force, Germany).
Collagen hydrolysates were dissolved in pure water at a
concentration of 10 ng/mL, adsorbed onto mica discs (Plano,
Germany), incubated for 15 min at room temperature, dried with
nitrogen, and imaged under air in tapping mode with OMCL-
AC240TS-W2 cantilevers (Atomic force). The data were processed
using the MFP-3D interface built on IGOR PRO version 6.02A
[14,15].
Nuclear Magnetic Resonance (NMR) Spectroscopy
One- and two-dimensional proton NMR spectra can be used to
describe various collagen hydrolysates in respect to their charac-
teristic chemical shift patterns. In order to identify the diverse
proton resonance signals, which can be assigned by their ppm
values to, for example, hydrogen atoms of Arg residues in the
collagen fragments, two-dimensional NMR spectra are necessary.
Two-dimensional NOESY (nuclear Overhauser spectroscopy)
NMR experiments provide information about the magnetization
transfer between hydrogen atoms that are nearby in space to each
other. With two-dimensional TOCSY (total correlation spectros-
copy) NMR experiments, one can analyze the magnetization
transfer via the chemical bonds. In combination, both two-
dimensional NMR techniques are sufficient for delivering charac-
teristic fingerprints of the collagen hydrolysates under study.
The NMR samples (collagen hydrolysates) were dissolved at an
amount of 3 mg in 0.5 ml water (90% H2O/10% D2O). The
NMR experiments were performed on a 600 MHz Bruker Avance
III spectrometer at 298K. 2D-TOCSY experiments (DIPSI-2;
mixing time 80 ms) and 2D-NOESY (mixing times 200 or 400 ms)
were recorded with 512 (F1)61024 (F2) complex data points and a
spectral width of 7212 Hz (12 ppm). Water suppression was
performed using excitation sculpting, and 16 scans per increment
were accumulated with an inter-scan recovery delay of 1.5 s. For
processing, we used zero-filling to 1024 (F1)62048 (F2) data points
prior to Fourier transformation, followed by baseline correction in
both dimensions. Spectra were calibrated on internal water.
Specimen Selection
Articular cartilage was obtained in full thickness from the lateral
femoral condyles of OA patients undergoing knee replacement
surgery (collagen biosynthesis experiments: N= 12, age 65.969.8
y, BMI 31.765.9; cartilage degradation experiments: N= 5, age
61.0613.4 y, BMI 30.564.3). The degree of OA changes of
femoral condyles was subsequently determined according to
Collins [25]. Four-millimeter-diameter cartilage discs were washed
three times with Geys balanced salt solution (GBSS) and
subsequently cultured as described below. The time needed to
process cartilage obtained from surgery to culture was always
below 4 hours. OA patients were selected at random from our
clinic. The use of human articular cartilage for this study was
approved by the local ethics committee of Justus-Liebig-University
of Giessen (Germany), and all patients provided written informed
consent before starting the experiments.
Articular Cartilage Explant Culture
Cartilage explants from mild (Collins grade,1.5) or moderately
(Collins grade 1.5–3) affected lateral human OA condyles were
Figure 2. Three-dimensional AFM picture (top) and NMR-TOCSY spectra (middle, bottom) of collagen hydroylsates. The AFM picture
(Fig. 2 top) shows the amorphous crystal-like structures in the presented 25 square micrometer area (0 to 5 micrometer) with a high resolution in the
third dimension (0 to 150 nanometer), demonstrating that no higher-ordered collagen structures (eg, triple-helical collagen fragments) are present in
the collagen hydrolysate preparation (RDH) from Rousselot. The highly resolved proton-NMR signals are displayed along the F1 and the F2 axes
according to their ppm values (Fig. 2 middle and bottom). F1 is frequency axis one, F2 is the second frequency axis. The ppm values on both
frequency axes correspond to the ppm values of the one-dimensional NMR spectrum. Depending on the relation of the magnetization transfer (via
the bonds: TOCSY, via space: NOESY), an assignment of the signals to the protons is possible and thus leads to a characteristic fingerprint pattern of
the collagen hydrolysate investigated (Fig. 2 middle and bottom). The TOCSY spectra (Fig. 2 middle and bottom) show, for example, one obvious
difference in their signal patterns–namely, the characteristic cross-peak at F1: 1.5 ppm/F2: 7.2 ppm, highlighted as a grey circle in the TOCSY
spectrum of RDH (Fig. 2 middle), is missing in the TOCSY spectrum of RDH-N (Fig. 2 bottom). This observation makes it clear that the fragments that
belong to this cross-peak are missing in the sample RDH-N (Fig. 2 bottom). Thus, one change in the cross-peak signal pattern is already enough to
distinguish between different collagen hydrolysates.
doi:10.1371/journal.pone.0053955.g002
Figure 3. Effect of collagen hydrolysates on the collagen
synthesis of OA cartilage. Incorporation of [3H]-proline and [14C]-
proline into collagen of human cartilage explants was determined by
measuring the radioactivity found in hydroxyproline. The [14C/3H]-
incorporation ratio was then calculated and is expressed as percent of
untreated control (100%) in the presence of 0.1, 0.5, 1, 2, and 10 mg/ml
of RDH, RDH-N, or CH-AlphaH. Each experiment was done with explants
removed from the lateral condyle of 6 patients graded with a Collins
score of ,1.5 and another 6 patients who presented lateral condyles
with a Collin score between 1.5 and 3. Thus, explants from a total of 12
patients were used. Data shown are the mean6standard deviation
(N = 12). Statistically significant different from untreated controls:
**0.001,p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0053955.g003
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cultured separately in 2.0 ml Ham’s F-12, 2.5 mM HEPES
(pH 7.2) containing 30 mg/ml alpha-ketoglutarate, 300 mg/ml
glutamine, 50 mg/ml ascorbate, 1.0 mM Na2S04, 20 units/ml
penicillin, 10 mg/ml streptomycin, 2.5 mg/ml amphotericin B and
50 mg/ml gentamycin, 485 mg/ml CaCl2x2H20 and 1% (v/v) CR-
ITS+TM Premix (Collaborative Biomedical Products, Bedford,
MD) [26–28]. Explants were cultured for 4–6 days in a normal
bench top CO2-incubator under sterile conditions in order to first
stabilize the cartilage metabolism at 37uC, 5% CO2, and 95%
relative humidity.
The collagen biosynthesis was determined by isolating radioac-
tive hydroxyproline after a novel dual radiolabeling procedure
developed by Goodwin et al. [29] to minimize the heterogeneity
among pairs of samples by using [3H]-proline as a baseline
measurement and [14C]-proline incorporation during experimen-
tal treatment so that each explant has its own internal control. For
dual radiolabeling, media were changed, explants were labeled for
24 h with 20 mCi/ml L-[2,3-3H]-proline (Perkin Elmer, Boston,
MA) in the presence of 50 mg/ml freshly prepared ascorbic acid.
Explants were washed several times in order to remove
unincorporated [3H]-proline, as controlled by determination of
radioactivity within wash solutions by liquid scintillation counting.
Media were added, and cartilage explants were radiolabeled again
for 24 h with 10 mCi/ml L-[14C(U)]-proline after addition of
50 mg/ml freshly made ascorbic acid in the presence of 0–10 mg/
ml collagen hydrolysates. At the end of this second radiolabeling
period, explants were washed three times with GBSS to remove
unincorporated radioisotopes, as checked by liquid scintillation
counting. Explants in GBSS and collected media were mixed with
10% (v/v) protease inhibitor cocktail (CompleteTM, Roche,
Penzberg, Germany) according to the manufacturer’s instructions
and stored frozen at 220uC until analysis.
In two separate sets of experiments, cartilage degradation was
determined in the presence or absence of 5.0 ng/ml recombinant
human interleukin-1ß (IL-1ß). Only lateral condyles of patients
with cartilage of Collins grade 1,5–3 were used, and again, the
metabolism of cultured explants was first stabilized for 4–6 days. In
the first set of experiments, explants from 5 different patients were
cultured for a period of 6 days in the presence of 0–10 mg/ml
collagen hydrolysates with a media change after 3 days, and the
loss of collagen, proteoglycans, matrix metalloproteinases (MMPs),
NO, and prostaglandin E2 (PGE2) from explants into nutrient
media was determined. In the second set of experiments, explants
from 6 additional different patients received IL-1ß together with
0–10 mg/ml collagen hydrolysates and NO, and proteoglycan loss
was evaluated during a culture period of 3 days. Media and
explants were frozen at 220uC in the presence of proteinase
inhibitors until analysis.
Determination of Collagen Synthesis
Dual radiolabeled cartilage explants were thawed and washed
three times with 1.0 ml GBSS. Excess liquid was removed by
Figure 4. Concentration-dependent effect of collagen hydrolysates on the synthesis and/or release of MMP-1, MMP-3, and MMP-
13. MMPs were determined within nutrient media of cultured human articular cartilage. Following stabilization of explant metabolism for 4–6 days,
explants were treated for additional 6 days with 0–10 mg/ml collagen hydrolysate. MMPs were determined with ELISA, and data are expressed as
mean6standard deviation (N= 5). Statistically significant different from untreated controls: *0.01,p#0.05, **0.001,p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0053955.g004
Figure 5. Concentration-dependent effect of collagen hydrolysates on the synthesis and/or release of NO and PGE2. ELISA was used
to determine NO and PGE2 in media of cultured articular cartilage explants treated with 0–10 mg/ml collagen hydrolysates. Data are expressed as
mean6standard deviation (N= 5). Statistically significant different from untreated controls: *0.01,p#0.05, **0.001,p#0.01, ***p#0.001.
doi:10.1371/journal.pone.0053955.g005
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blotting the specimen on filter paper, and tissue wet weights were
determined. Explants were dried at 30uC after treatment with
acetone; the dry weight was determined and then hydrolyzed for
18–24 h at 108uC with 0.6 ml 6 N HCl. Radioactive hydroxy-
proline was assayed by using a method described by Juva and
Prockop [30], as modified by Switzer and Summer [31].
Preliminary experiments revealed that unincorporated radioactive
precursors were removed completely by this procedure. The
radioactivity of both [3H]- and [14C]-labeled hydroxyproline
oxidation products was normalized with respect to the dry weights
of explants. [3H]-radioactivity was used as internal control by first
calculating the (14C/3H) ratio of explants, as described by
Goodwin et al. [29]. This ratio was then used to determine the
percentage of collagen synthesis of treated explants versus
untreated ( = 100%) controls. Thus, the untreated controls provide
the basal ratio against which the treated explants are compared.
Analysis of Collagen Loss
Collagen fragments released from the explants were determined
in nutrient media using a commercially available collagen type II
ELISA (MD Bioproducts, Zurich, Switzerland) according to the
instructions provided by the manufacturer. Preliminary experi-
ments revealed that none of the collagen hydrolysates was detected
by this ELISA, indicating that peptides were mainly derived from
collagen type I. Data were normalized by the cartilage wet weight.
Analysis of Proteoglycan Loss
Papain-digested cartilage explants and culture media were
assayed for sulfated glycosaminoglycans (GAGs) by reaction with
0.25 ml 1,9-dimethylmethylene blue dye solution (Serva, Heidel-
berg, Germany) in polystyrene 96-well plates and quantified by
spectrophotometry at 523 nm using an ELISA plate reader.
Chondroitin sulfate A from bovine trachea (Sigma, St. Louis, MO)
was used as the standard [28,32]. Proteoglycan loss was then
calculated from the ratio of GAGs found in the media to total
GAGs found in media plus explants. Data were normalized by the
cartilage wet weight.
Determination of NO Production
Nitrite levels in media were measured in duplicate using the
Griess reaction with sodium nitrite as standard as described earlier
[27,28,33]. Briefly, nitrate, being present in 0.1 ml media, was first
reduced at 37uC for 20 minutes using 10 ml nitrate reductase
(0.4 U/ml, Roche Diagnostics GmbH, Mannheim, Germany).
Media samples were then mixed with an equal volume of Griess
reagent (1% sulfanilamide and 0.1% N-1-naphthylethylenedia-
mine dihydrochloride in 25% (v/v) H3PO4) and incubated for 5
minutes at room temperature, and the optical density was
measured at 523 nm in an ELISA photometer [27,28,33]. Data
were normalized by the cartilage wet weight.
Determination of PGE2, MMPs and TIMP-1
PGE2, MMP-1, -3, and -13; and TIMP-1 within media were
measured using commercially available ELISA kits (PGE2-kit from
Cayman, Ann Arbor, MI; MMP-1-kit from Calbiochem, Darm-
stadt, Germany; TIMP-1-, MMP-3- and MMP-13-kit from GE
Healthcare, Little Chalfont, UK) according to the instructions
provided by the manufacturers. Preliminary experiments revealed
that none of the collagen hydrolysates tested interfered with the
ELISAs used. Data were normalized by the cartilage wet weight.
Chondrocyte Viability
The viability of chondrocytes within each of the anatomical
zones of cartilage explants (superficial, intermediate, and deep
layer) was determined in slices of separately cultured explants
treated with or without 10 mg/ml collagen hydrolysates using the
fluorescent probes fluorescein diacetate (Sigma, St. Louis, MO)
and propidium iodide (Sigma, St. Louis, MO) as described
previously [28,34]. Briefly, at the end of the experiments, cartilage
explants were washed twice with sterile isotonic phosphate-
buffered saline (PBS). Tissue sections were then cut perpendicular
to the joint surface, each being 100 mm thick. Cartilage slices were
placed in a small drop of sterile PBS on a glass slide; 200 ml Ham’s
F-12 media containing 0.1 mM fluorescein diacetate and 0.3 mM
propidium iodide were added and subsequently incubated in the
dark at 37uC and 95% humidity for 5 min. At two sites of the 3
slices per explant, at least 50 viable and/or dead cells, as indicated
by green or red fluorescence, were counted in each of the 3
cartilage layers (superficial, intermediate, and deep zone) under a
fluorescence microscope at 200-fold magnification.
Statistical Analysis
Each experimental condition was repeated four (cartilage
degradation), five (cartilage degradation in the presence of IL-
1ß), or 11 times (collagen synthesis) using explants obtained from
5, 6, or 12 different patients, respectively (n = 5, 6 or 12). The data
obtained from treated explants were compared with values from
untreated controls from the same joint. Groups of data were
evaluated using one-way analysis of variance (ANOVA) and the
Friedman test. Data presented are mean6standard deviation, and
the significance was set to p#0.05.
Results
Biochemical Characterization of Collagen Hydrolysates
MALDI-TOF-MS analysis revealed qualitative differences
between collagen hydrolysates obtained from different sources
with respect to peptides identified in each preparation, width of
molecular weight distribution, and the average molecular weight.
Peaks identified from mass spectra obtained from both the linear
(Figure 1A–C) and reflector (Figure 1D–F) modes clearly showed
marked differences in the composition of peptides between
collagen hydrolysates tested. The molecular weight distribution
of peptides and the average molecular weight obtained from mass
spectra in the linear mode for RDH (3,500 Da) were somewhat
larger than those obtained from RDH-N (3,250 Da) and CH-
AlphaH (3,300 Da) (Figure 1A–C).
AFM-analysis, in combination with NMR spectroscopy,
revealed information about the aggregation behavior of the
fragments from the collagen hydrolysates studied. RDH occurred
in a smooth unstructured form, although some amorphous crystal-
like structures were visible (Figure 2 - top). When comparing the
TOCSY-spectrum of RDH with that of RDH-N, it was obvious
that in the RDH-N TOCSY-spectrum, some signals were missing
(Figure 2– middle and bottom). This observation clearly demon-
strates that larger fragments present in RDH are removed or split
off and that TOCSY experiments can be used as a fingerprint
method to identify even complex collagen hydrolysates. The
collagen fragments of RDH, RDH-N, and CH AlphaH analyzed
with 2D-TOCSY NMR experiments [15] together with DOSY-
NMR experiments [15] had a size range between 3.1–12.3 kDa
(Figure 3 - middle), 0.4–3.3 kDa (Figure 2 - bottom), and 2.9–
8.1 kDa, respectively.
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Effect of Collagen Hydrolysates on Collagen Synthesis
Even though the metabolism of cartilage from early stages of
OA disease is known to differ from those of late stages [e.g. 35,36],
we found that the response of early OA cartilage (Collins score
,1.5) to treatment with the three collagen hydrolysates was
statistically similar to cartilage with moderate OA alterations
(Collins score 1.5–3). Thus, data obtained for collagen synthesis
from cartilage with mild and moderately OA changes were
combined to n= 12, and statistical analysis was performed.
Figure 3 shows that RDH and CH-AlphaH inhibited collagen
synthesis concentration-dependently. However, a statistically
significant inhibition was seen only for concentrations at
0.5 mg/ml for RDH and 2.0 mg/ml for CH-AlphaH, as well as
at higher concentrations.
Effect of Collagen Hydrolysates on MMPs and TIMP-1
Since collagen type II fragments isolated from human OA
cartilage were reported to induce catabolic metabolism [12,13], we
also investigated whether collagen hydrolysates induce similar
effects. RDH was found to markedly and dose-dependently
increase the levels of MMP-1, -3, and -13 within nutrient media
by up to 40-fold, 12-fold, and 125-fold, respectively (Figure 4).
RDH-N was less active, in that a significantly increased amount of
MMP-1 (6-fold) was found only at a high concentration of 10 mg/
ml. The TIMP-1 levels remained unaffected by RDH and RDH-
N but were decreased in the presence of 10 mg/ml CH-AlphaH
(data not shown).
Effect of Collagen Hydrolysates on Collagen and
Proteoglycan Loss
In order to determine whether collagen fragments can induce
degradation of extracellular matrix, OA cartilage explants were
treated with RDH, RDH-N, or CH-AlphaH. Collagen hydroly-
sates, even when tested at a high concentration of 10 mg/ml or in
the presence of IL-1ß, did not induce any elevated loss of collagen
or proteoglycans from explants into nutrient media (data not
shown).
Effect of Collagen Hydrolysates on NO and PGE2
We next investigated the generation of PGE2 and NO,
important inflammatory mediators affecting proteoglycan and
collagen metabolism. Analysis of the NO secreted from treated
explants into nutrient media revealed that only RDH dose-
dependently augmented the content of NO (Figure 5). Further-
more, 1 mg/ml or higher concentrations of RDH as well as
10 mg/ml CH-AlphaH, but not RDH-N, induced significantly
elevated levels of PGE2 within media (Figure 5). The collagen
hydrolysates that were tested did not further enhance the level of
NO in media of IL-1ß-treated explants (data not shown).
Effect of Collagen Hydrolysates on the Viability of
Chondrocytes
In order to exclude the possibility that the results obtained were
due to impaired chondrocyte viability, cartilage sections were
stained with propidium iodide and fluorescein diacetate, and
subsequently, viable and dead cells were counted. Analysis of
sections revealed that none of the collagen hydrolysates tested at
the high concentration of 10 mg/ml induced any cytotoxic effects
on chondrocytes of the superficial, intermediate, or radial zones of
explants (data not shown).
Discussion
Besides extensive marketing of nutraceuticals, only limited
research about the efficacy, safety, and mechanisms of action has
been performed, which is partly due to the minimal legal
regulations when compared to the high statutory requirements
imposed onto drugs. Our study is focused on collagen hydroly-
sates, a nutraceutical that has enjoyed large public attention for
several years. We show for the first time that (1) the collagen
hydrolysates RDH, RDH-N, and CH-alphaH differ with respect to
both the molecular weight distribution of collagen fragments and
by their biological activities on human chondrocytes. We
demonstrate also for the first time that (2) none of the bovine
collagen hydrolysates tested had any stimulatory effect on the
biosynthesis of collagen by human articular knee cartilage and (3)
that only RDH induces catabolic factors, like NO, PGE2, and
MMPs, without resulting in any elevated degradation of the
extracellular matrix.
Our mass spectrometric analysis as well as NMR experiments
enabled us to show for the first time the different characteristic
composition and structural organization of the investigated bovine
collagen hydrolysates induced by various hydrolysis techniques
[14,15,37]. Furthermore, we report for the first time about the
different biological activities of collagen hydrolysates on human
articular chondrocytes, which might be due to different active
ingredient(s) of various collagen hydrolysate preparations, as
shown by our biophysical analysis. These active ingredients might
be either one or several oligopeptides or aggregates and remain to
be determined.
The present study was carried out in order to understand the
molecular mechanisms of the possible structure-modifying effect of
collagen hydrolysates, as has been insinuated both in an animal
model of OA and in a recently published clinical trial [8,38]. Our
study is the first to provide an in vitro demonstration of the lack of
stimulatory effect of three bovine collagen hydrolysates on the
biosynthesis of collagen by human OA knee cartilage. This
observation was even independent of the degree of OA alterations,
as found for cartilage explants. We investigated a broad range of
concentrations, including those used previously [10] and even
those being as high as 10 mg/ml, which are unlikely to be reached
or accumulated in vivo within the joints. Moreover, collagen
hydrolysates were used at concentrations that were thought to
cover the assumed therapeutic plasma levels, which are currently
unknown and which might lie below 1 mg/ml.
Our findings are in contrast to one previous study in which
bovine collagen hydrolysate was reported to stimulate collagen
biosynthesis by young bovine chondrocytes [10]. This discrepancy
may be due to differences in the analytical methods applied,
species, and age and health status of joints, which is in line with
previous studies reporting severe alterations in the metabolism of
cartilage due to age and OA [22–24]. In our study, we applied a
novel dual proline radiolabeling technology to reduce the
heterogeneity of biosynthetic data obtained when human cartilage
explants are investigated [29]. The determination of the rate of
radioactive proline incorporation without specific separation of
collagens from overall proteins does not reflect the true rate of
collagen synthesis, since the enrichment of proline in collagen as
compared with other proteins is not assigned [39]. Therefore, we
analyzed dual radiolabeled hydroxyproline to ensure that only the
biosynthesis of collagen type II exclusively was determined
[29,30,31]. Approximately up to 90% of total collagen in cartilage
is of type II, which is considered, together with type IX, X, and
XI, typical for cartilage and forms the backbone of cartilage
heteropolymeric fibrils.
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Cartilage destruction, mediated by the loss of collagen type II
and proteoglycans, is a characteristic feature of OA [40,41]. Using
human cartilage from autopsy and arthroplasty, it was shown that
during OA and aging, the initial damage to collagen type II occurs
in the superficial and upper middle zones and extends into the
deeper zones with increasing destruction. The initial injury is seen
around chondrocytes in the pericellular region, and OA cartilage
exhibits increased levels of cleaved and denatured collagen type II
[40,41]. Degradation of collagen type II is primarily mediated by
MMP-13 but also by MMP-1 and -3, whereas loss of proteogly-
cans has been directly correlated with IL-1-induced expression of
ADAMTS-4 and -5, followed by further enzymatic digestion by
MMP-3, for example [42]. Currently, four different TIMP species
have been identified, and only TIMP-3 has been shown to possess
the potential to inhibit both ADAMTS-4 and -5 [43,44]. Even
though we found that RDH can induce elevated levels of MMP-1,
-3, and -13 without changing the level of TIMP-1, this was not
mirrored by any elevated loss of proteoglycans or collagen. Our
findings indicate induction of TIMPs other than TIMP-1 like
TIMP-3, absence of proteolytic processing of proMMPs to active
MMPs and/or no effect of collagen hydrolysates on the expression
of the major aggrecanases ADAMTS-4 and/or ADAMTS-5.
In order to avoid the possibility that we might have overlooked
any pharmacological effect, we (a) used serum-free culture
conditions to prevent the presence of serum growth factors and
cytokines so that the responses solely due to collagen hydrolysates
were identified; (b) sorted our explants removed from the same
anatomical position according to the macroscopically visible
pathological changes; and (c) cultured them in the presence of
collagen hydrolysates over an extended period of six days. This
approach is in line with the current difficulty in obtaining a
comprehensive idea of the metabolic changes in OA due to the
diversity in gene expression [45,46]. This diversity may stem from
regional differences of cellular metabolism and also from more or
less OA-affected cartilage.
However, there are other components of cartilage breakdown
that need to be further assessed. In this line, we also investigated
whether collagen hydrolysates modulate the production respec-
tively release of NO and PGE2 and may thus alter the PG
synthesis and release using human explants [19]. RDH was found
to significantly induce the production of PGE2 in moderately OA-
affected cartilage. Attur et al. [19] reported that the predominant
effects of PGE2 in OA chondrocytes are catabolic, in that PGE2
inhibits proteoglycan synthesis and stimulates matrix degradation
in OA chondrocytes via the EP4 receptor. Even though RDH
significantly increased the PGE2 level in our explant cultures, we
observed no higher loss of proteoglycan and collagen. Increased
NO synthesis has been associated with upregulated MMP activity,
as has been also determined in our experiments [18]. However,
the RDH-induced raised NO level does not correlate with any
elevated loss of proteoglycans, which might be due to unaltered
expression and/or activity of ADAMTS-4 and -5. These
aggrecanases have to cleave aggrecan first before MMPs can
further digest this proteoglycan.
In conclusion, our study has clearly elaborated for the first time
that collagen hydrolysates from various sources differ significantly
with respect to both their chemical composition of oligopeptides
representing collagen fragments as well as their effects on human
articular cartilage. Since marked effects on human chondrocytes
were observed, depending on the collagen hydrolysates prepara-
tion investigated, our in vitro study indicates that collagen
hydrolysates used as nutriceuticals might be either ineffective or
even detrimental to OA cartilage. However, metabolized collagen
fragments or other collagen hydrolysate preparations might
contain therapeutically useful peptides. Thus, their biomedical
properties have to be studied thoroughly both in vitro and in
animal as well as clinical trials before being applied as safe and
effective nutriceuticals in patients.
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